Oramed Pharmaceuticals Inc. (ORMP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ORMP POWR Grades
- Sentiment is the dimension where ORMP ranks best; there it ranks ahead of 54.67% of US stocks.
- ORMP's strongest trending metric is Value; it's been moving down over the last 179 days.
- ORMP ranks lowest in Quality; there it ranks in the 9th percentile.
ORMP Stock Summary
- Oramed Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 7.56% of US listed stocks.
- The ratio of debt to operating expenses for Oramed Pharmaceuticals Inc is higher than it is for about merely 6.54% of US stocks.
- With a price/sales ratio of 133.42, Oramed Pharmaceuticals Inc has a higher such ratio than 98.04% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Oramed Pharmaceuticals Inc, a group of peers worth examining would be FGEN, APTX, KLDO, MTEM, and RAPT.
- ORMP's SEC filings can be seen here. And to visit Oramed Pharmaceuticals Inc's official web site, go to www.oramed.com.
ORMP Valuation Summary
- ORMP's price/sales ratio is 236.9; this is 6134.21% higher than that of the median Healthcare stock.
- ORMP's price/sales ratio has moved NA NA over the prior 174 months.
- Over the past 174 months, ORMP's EV/EBIT ratio has gone down 0.8.
Below are key valuation metrics over time for ORMP.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ORMP | 2021-08-31 | 236.9 | 9.4 | -34.0 | -32.6 |
| ORMP | 2021-08-30 | 227.5 | 9.0 | -32.7 | -31.2 |
| ORMP | 2021-08-27 | 225.2 | 8.9 | -32.4 | -30.8 |
| ORMP | 2021-08-26 | 214.1 | 8.5 | -30.8 | -29.2 |
| ORMP | 2021-08-25 | 211.3 | 8.4 | -30.4 | -28.7 |
| ORMP | 2021-08-24 | 194.3 | 7.7 | -27.9 | -26.2 |
ORMP Growth Metrics
- The 4 year revenue growth rate now stands at 2068.8%.
- Its 5 year revenue growth rate is now at 2068.8%.
- Its 3 year revenue growth rate is now at 1959.2%.
The table below shows ORMP's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 2.703 | -21.932 | -24.766 |
| 2021-09-30 | 2.703 | -21.181 | -22.238 |
| 2021-06-30 | 2.701 | -17.497 | -18.799 |
| 2021-03-31 | 2.701 | -15.216 | -15.458 |
| 2020-12-31 | 2.71 | -15.596 | -14.538 |
| 2020-09-30 | 2.71 | -12.44 | -11.511 |
ORMP's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ORMP has a Quality Grade of D, ranking ahead of 13% of graded US stocks.
- ORMP's asset turnover comes in at 0.047 -- ranking 325th of 681 Pharmaceutical Products stocks.
- EDSA, RGEN, and STAB are the stocks whose asset turnover ratios are most correlated with ORMP.
The table below shows ORMP's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-05-31 | 0.047 | 1 | -0.870 |
| 2021-02-28 | 0.056 | 1 | -0.619 |
| 2020-11-30 | 0.067 | 1 | -0.614 |
| 2020-08-31 | 0.071 | 1 | -0.461 |
| 2020-05-31 | 0.076 | 1 | -0.408 |
| 2020-02-29 | 0.081 | 1 | -0.501 |
ORMP Price Target
For more insight on analysts targets of ORMP, see our ORMP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $23.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
ORMP Stock Price Chart Interactive Chart >
ORMP Price/Volume Stats
| Current price | $4.56 | 52-week high | $31.54 |
| Prev. close | $4.52 | 52-week low | $3.59 |
| Day low | $4.40 | Volume | 544,400 |
| Day high | $4.68 | Avg. volume | 745,125 |
| 50-day MA | $4.86 | Dividend yield | N/A |
| 200-day MA | $12.95 | Market Cap | 175.85M |
Oramed Pharmaceuticals Inc. (ORMP) Company Bio
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company was founded in 2002 and is based in Jerusalem, Israel.
Latest ORMP News From Around the Web
Below are the latest news stories about Oramed Pharmaceuticals Inc that investors may wish to consider to help them evaluate ORMP as an investment opportunity.
ORMP: Moving Multiple Candidates & Studies ForwardBy M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oral COVID vaccine pill moving forward in several key international markets… Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) continues to advance its assets, and expand its management team and financial flexibility to support its growth initiatives. Oravax has secured pre-orders for Oravax’s COVID-19 oral vaccine, strengthened its cash position |
We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX), Oramed Pharmaceuticals (ORMP) and Citius Pharmaceuticals (CTXR)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTX – Research Report), Oramed Pharmaceuticals (ORMP – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments. Repare Therapeutics (RPTX) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics, with a price target of $54.00. The company's shares closed last Friday at $15.23, close to its 52-week low of $13.97. According to TipRanks. |
Oramed Issues Annual Message to ShareholdersOramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. To see a video message from the CEO please click here: https://www.youtube.com/watch?v=vgq1I7ylKsk |
Oramed Pharmaceuticals Updates 1 Key Risk FactorShares of oral drug delivery systems, Oramed Pharmaceuticals, Inc. (ORMP) have gained 180.3% over the past year. OMRP is focused on developing solutions for the treatment of diabetes, with two pipeline candidates - ORMD-0801 and ORMD-0901. ORMD-0801 is being developed for treating diabetes and is currently under Phase-3 studies. Notably, ORMD-0801 can potentially become the first oral insulin capsule available commercially. Meanwhile, ORMD-0901 is targeted for type-2 diabetes. Moreover, Oravax Medical, wherein Oramed is the largest shareholder, recently entered into a cooperation and purchase agreement with Vietnam’s Tan Thanh Holdings. This agreement includes a 10 million dose pre-order of oral COVID-19 vaccines from Oravax (currently under development). |
ORMP Price Returns
| 1-mo | N/A |
| 3-mo | -47.28% |
| 6-mo | -68.07% |
| 1-year | -65.92% |
| 3-year | 27.02% |
| 5-year | -41.31% |
| YTD | -68.07% |
| 2021 | 236.79% |
| 2020 | -17.67% |
| 2019 | 71.67% |
| 2018 | -66.67% |
| 2017 | 47.06% |
Continue Researching ORMP
Want to see what other sources are saying about Oramed Pharmaceuticals Inc's financials and stock price? Try the links below:Oramed Pharmaceuticals Inc (ORMP) Stock Price | Nasdaq
Oramed Pharmaceuticals Inc (ORMP) Stock Quote, History and News - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...